CoChat

Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery

Open access
Jiang, Xue-Yang, Chen, Ting-Kai, Zhou, Jun-Ting, He, Si-Yu, Yang, Hong-Yu, Chen, Yao, Qu, Wei, Feng, Feng, Sun, Hao-Peng · 2018 · ACS Medicinal Chemistry Letters

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Designing multitarget-directed ligands (MTDLs) is considered to be a promising approach to address complex and multifactorial maladies such as Alzheimer’s disease (AD). The concurrent inhibition of the two crucial AD targets, glycogen synthase kinase-3β (GSK-3β) and human acetylcholinesterase ( h AChE), might represent a breakthrough in the quest for clinical efficacy. Thus, a novel family of GSK-3β/AChE dual-target inhibitors was designed and synthesized. Among these hybrids, 2f showed the most promising profile as a nanomolar inhibitor on both h AChE (IC 50 = 6.5 nM) and h GSK-3β kinase activity (IC 50 = 66 nM). It also showed good inhibitory effect on β-amyloid self-aggregation (inhibitory rate = 46%) at 20 μM. Western blot analysis revealed that compound 2f inhibited hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells. In vivo studies confirmed that 2f significantly ameliorated the cognitive disorders in scopolamine-treated ICR mice and less hepatotoxicity than tacrine. This study provides new leads for assessment of GSK-3β and AChE pathway dual inhibition as a promising strategy for AD treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsmedchemlett.7b00463

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. Dolan P. J., 2010, Curr. Opin. Drug Disc., 13, 595
  2. Zemek F., 2014, Expert Opin. Drug Saf., 13, 759

Cited by

See all 142

Metadata

Authors
Jiang, X.-Y., Chen, T.-K., Zhou, J.-T., He, S.-Y., Yang, H.-Y., Chen, Y., Qu, W., Feng, F., & Sun, H.-P.
Affiliations
  • Department of Natural Medicinal Chemistry and ‡Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
  • China Pharmaceutical University (CN)
  • Nanjing University of Chinese Medicine (CN)
Corresponding author
Feng, Feng
Venue
ACS Medicinal Chemistry Letters
Published
2018-02-09
Volume
9
Issue
3
Pages
171-176
ISSN
1948-5875 (ISSN-L)
OpenAlex
W2786033877
Cited by
122
References
34
Citations by year
2026: 12 · 2025: 18 · 2024: 21 · 2023: 12 · 2022: 14 · 2021: 9 · 2020: 14 · 2019: 17 · 2018: 5
FWCI
8.55
Type
journal article
Language
en
Open access
Locations
  • ACS Medicinal Chemistry Letters (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministry of Education of the People's Republic of China (2015ZD009)
  • Natural Science Foundation of Jiangsu Province (BK20140957)
  • Government of Jiangsu Province
  • National Natural Science Foundation of China (81373956, 81402851, 81573281)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords
Alzheimer's disease, multi-target-directed ligands, GSK-3β inhibition, acetylcholinesterase inhibition, dual inhibitors, amyloid-beta aggregation, tau hyperphosphorylation, tacrine, scopolamine-induced cognitive impairment, hepatotoxicity, drug discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery. https://app.cochat.ai/papers/10.1021/acsmedchemlett.7b00463
The paper
Jiang, X.-Y., Chen, T.-K., Zhou, J.-T., He, S.-Y., Yang, H.-Y., Chen, Y., Qu, W., Feng, F., & Sun, H.-P. (2018). Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer’s Disease Drug Discovery. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.7b00463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.